The government has given approval to Aurobindo Pharma under the PLI scheme for promotion of domestic manufacturing of critical bulk drugs. The Production Linked Incentive (PLI) scheme aims at promotion of manufacturing of critical key starting materials (KSMs)/drug intermediates and APIs in the country.
The Ministry of Chemicals and Fertilizers said the applications of Aurobindo Pharma (through Lyfius Pharma) have been approved for setting up plants for the production of Penicillin G, and 7-ACA, with committed production capacity of15,000 MT and 2,000 MT, respectively. The committed investment for Penicillin G is Rs1,392 crore, and for 7-ACA is Rs 813 crore.
The approval has also been given to Aurobindo Pharma (through Qule Pharma) for setting up plant for production of Erythromycin Thiocyanate (TIOC), with committed production capacity of1,600 MT at a committed investment of Rs 834 crore.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1620.50 |
Dr. Reddys Lab | 6171.85 |
Cipla | 1494.65 |
Zydus Lifesciences | 1013.75 |
Lupin | 1617.85 |
View more.. |